Ramoril Plus5 mg+25 mg

Ramoril Plus is a fixed-dose combination of an angiotensin-converting enzyme (ACE) inhibitor and a thiazide diuretic, indicated for:

• Established use: Treatment of hypertension (high blood pressure) in adult patients who are not adequately controlled on either component alone, or as a continuation therapy in patients already stabilised on the individual components given in the same proportion.

Ramoril Plus is not recommended as initial therapy for hypertension; it is intended for patients whose blood pressure requires treatment with both agents, generally after dose titration of the individual components.

Each tablet of Ramipril + Hydrochlorothiazide contains ramipril (an ACE inhibitor) and hydrochlorothiazide (a thiazide diuretic) in fixed-dose combinations, commonly available as 2.5 mg + 12.5 mg and 5 mg + 25 mg strengths.

Ramoril Plus combines two complementary antihypertensive mechanisms in a single tablet. Ramipril is an ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that increases renal excretion of sodium, chloride, and water, reducing plasma volume. Used together, Ramoril Plus provides additive blood pressure-lowering effects, and the ACE-inhibitor component helps offset the potassium loss caused by the diuretic component.

Ramoril Plus belongs to the therapeutic class of antihypertensive combination agents, specifically an ACE inhibitor combined with a thiazide diuretic.

Ramipril + Hydrochlorothiazide works through two complementary mechanisms:

• Ramipril is a prodrug converted in the liver to ramiprilat, its active metabolite. Ramiprilat inhibits angiotensin-converting enzyme, reducing conversion of angiotensin I to the potent vasoconstrictor angiotensin II. This lowers peripheral vascular resistance, reduces aldosterone secretion, and lowers blood pressure without causing reflex tachycardia.
• Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule of the kidney, increasing excretion of sodium, chloride, and water, which reduces plasma and extracellular fluid volume and lowers blood pressure.

The combination in Ramipril + Hydrochlorothiazide produces an additive antihypertensive effect, and the ACE-inhibitor component tends to counteract the hypokalemia that hydrochlorothiazide alone can cause.

Ramoril Plus should be taken orally, once daily, at approximately the same time each day, preferably in the morning, with or without food. Tablets should be swallowed whole with a glass of water.

Ramoril Plus has several clinically significant drug interactions:

• Potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium: increased risk of hyperkalemia due to the ramipril component.
• NSAIDs (including selective COX-2 inhibitors): may reduce the antihypertensive effect and increase the risk of renal impairment, particularly in volume-depleted patients.
• Lithium: both ACE inhibitors and thiazide diuretics can reduce lithium clearance, increasing the risk of lithium toxicity; concurrent use should be monitored closely.
• Aliskiren: concomitant use is contraindicated in patients with diabetes and not recommended in others with renal impairment due to increased risk of hyperkalemia, hypotension, and renal dysfunction.
• Other antihypertensives, diuretics, or vasodilators: additive hypotensive effect.
• Antidiabetic agents (insulin, oral hypoglycemics): ramipril may enhance the glucose-lowering effect, while hydrochlorothiazide may impair glucose tolerance; blood glucose should be monitored.
• Corticosteroids and other agents causing electrolyte loss: may increase risk of hypokalemia.

Common and important side effects of Ramoril Plus include:

• Very common/common: dizziness, headache, persistent dry cough, hypotension (especially after the first dose), fatigue, and gastrointestinal disturbances (nausea, vomiting).
• Electrolyte disturbances: hyperkalemia (from ramipril) or hypokalemia, hyponatremia, and hypomagnesemia (from hydrochlorothiazide); net potassium effect varies by patient.
• Uncommon but important: angioedema (of the face, lips, tongue, glottis, and/or larynx) - a rare but potentially life-threatening reaction requiring immediate discontinuation and emergency medical attention if airway involvement occurs.
• Other effects: hyperuricemia and gout flares, photosensitivity reactions, hyperglycemia, hyperlipidemia, and rarely, blood dyscrasias.

Patients should seek urgent medical care for swelling of the face/throat, difficulty breathing, or severe skin reactions.

Ramoril Plus carries a boxed warning: when used during pregnancy, ACE inhibitors can cause injury and even death to the developing fetus. Ramoril Plus is contraindicated in pregnancy; if pregnancy is detected, it should be discontinued as soon as possible.

It is not known whether ramipril or hydrochlorothiazide pass into breast milk in clinically significant amounts, but thiazides are known to be excreted in breast milk and may suppress lactation. Use during breastfeeding is generally not recommended; a physician should be consulted to weigh potential risks against the need for therapy, and alternative agents are usually preferred while breastfeeding.

Ramoril Plus requires caution in the following situations:

• Hypotension: symptomatic hypotension may occur, particularly after the first dose in volume- or salt-depleted patients (e.g., from prior diuretic use, dietary salt restriction, vomiting, or diarrhea); correct volume depletion before starting therapy where possible.
• Renal impairment / bilateral renal artery stenosis: may cause deterioration in renal function; use with caution and monitor renal function, especially in patients with renovascular disease.
• Electrolyte imbalance: monitor serum potassium (risk of hyperkalemia from ramipril balanced against hypokalemia from hydrochlorothiazide) and sodium periodically, especially in the elderly and those on other electrolyte-affecting drugs.
• Angioedema: see Side Effects and Contraindications; requires immediate discontinuation and monitoring if it occurs.
• Persistent dry cough: a known class effect of ACE inhibitors; usually resolves after discontinuation.
• Diabetes mellitus: hydrochlorothiazide may worsen glycemic control; monitor blood glucose. Concomitant use with aliskiren is contraindicated in diabetic patients.
• Gout: hydrochlorothiazide can precipitate acute gout attacks by reducing uric acid clearance.
• Surgery/anesthesia: may increase risk of hypotension.

Overdose of Ramoril Plus may cause pronounced hypotension, electrolyte disturbances (especially hypokalemia or hyperkalemia), dehydration, and acute kidney injury. If overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center right away. Treatment is generally supportive and may include volume and electrolyte replacement under medical supervision; do not attempt to manage an overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: Ramoril Plus should be used cautiously with dose adjustment in patients with mild-to-moderate renal impairment (creatinine clearance 30-60 mL/min); it is generally not recommended in patients with severe renal impairment or anuria.

Hepatic impairment: use with caution; hepatic conversion of ramipril to its active metabolite may be reduced, and thiazides may precipitate hepatic encephalopathy in patients with impaired hepatic function or progressive liver disease.

Elderly: may be more sensitive to hypotensive and renal effects; start at the lowest available dose and monitor closely.

Pediatric patients: see Pediatric Uses.

Pregnancy and lactation: see Pregnancy and Lactation.

Ramoril Plus is generally used as long-term, ongoing therapy for chronic hypertension. Duration should be determined by the treating physician based on blood pressure control, tolerability, and periodic reassessment of renal function and electrolytes.

ACE inhibitor + thiazide diuretic fixed-dose combination (antihypertensive combination agent).

Ramipril + Hydrochlorothiazide lowers blood pressure through complementary mechanisms: the ramipril component inhibits angiotensin-converting enzyme, reducing angiotensin II-mediated vasoconstriction and aldosterone release, while the hydrochlorothiazide component reduces plasma volume by increasing renal sodium and water excretion. Together these mechanisms produce an additive antihypertensive effect.

D

The safety and efficacy of Ramoril Plus in pediatric patients have not been established. Its use in children is generally not recommended due to lack of adequate data on dosing, safety, and effectiveness in this population.